POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.22.2021, 12:50pm CEST, WHO):   India 53,256    Brazil 44,178    France 1,815    Turkey 5,091    Russia 17,378    The United Kingdom 9,072    Argentina 10,395    Columbia 27,818    Iran 10,485    Mexico 1,578    Peru 2,896    Indonesia 14,536    South Africa 13,155    Chile 5,205    Philippines 5,249    Iraq 5,235    Bangladesh 4,636    Japan 1,011    Malaysia 4,611    Nepal 1,584    United Arab Emirates 1,964    Saudi Arabia 1,212    Bolivia 1,086    Paraguay 1,145    Tunisia 2,478    Uruguay 1,488    Kuwait 1,935    Venezuela 1,327    Oman 2,529    Thailand 3,175    Cuba 1,561    Zambia 2,060    Afghanistan 1,847    Mongolia 2,268    Namibia 1,403    Uganda 1,367    China 103    Singapore 16    New Zealand 0    Australia 25    South Korea 395   

EMA evaluating use of Moderna COVID-19 vaccine in people aged 12 to 17

Christian Fernsby |
EMA evaluating use of COVID-19 Vaccine Moderna in young people aged 12 to 17EMA has started evaluating an application to extend the use of the COVID-19 Vaccine Moderna to include young people aged 12 to 17.

Article continues below




COVID-19 Vaccine Moderna is a vaccine for preventing COVID-19. It is currently authorised for use in people aged 18 and older. It contains a molecule called messenger RNA (mRNA) with instructions for producing a protein known as the spike protein, which is naturally present in SARS-CoV-2, the virus that causes COVID-19. The vaccine works by preparing the body to defend itself against SARS-CoV-2.

EMA’s human medicines committee (CHMP) will carry out an accelerated assessment of data submitted in the application, including results from a large ongoing clinical study involving adolescents from 12 to 17 years of age. This study was carried out in accordance with the paediatric investigation plan (PIP) for COVID-19 Vaccine Moderna, which was agreed by EMA's Paediatric Committee (PDCO).

The CHMP’s opinion on extending the use of the vaccine, together with any requirements for further studies and additional safety monitoring, will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.



What to read next

Moderna says its coronavirus vaccine candidate is stable in standard home refrigerator
EMA recommends COVID-19 Vaccine Moderna for authorisation in EU
U.S. authorizes Moderna's coronavirus vaccine for emergency use